88 reports

  • GENETIC DISORDERS, COMMON SYMPTOMS OF GENETIC DISORDERS
  • GENETIC DISORDERS, PROGRESSION OF CF

Global Genetic Disorders Drugs Market to 2023 - A Rapidly Growing Treatment Landscape Driven by Targeted Complement System Inhibitors and Enzyme Replacement Therapies to Treat PNH and Lysosomal Storage Disease Summary Genetic disorders are caused by abnormalities in a person’s genome and represent...

  • Genetic Disorder
  • World
  • Market Size
  • Alexion Pharmaceuticals, Inc.
  • Alnylam Pharmaceuticals, Inc.

Global Genetic disorders Partnering 2012-2018: Deal trends, players and financials Executive Summary Chapter ## – Introduction Chapter ## – Trends in Genetic Disorders dealmaking ##. ##.

  • Genetic Disorder
  • Pathology
  • World
  • Demand
  • Genetic diseases
  • Non-genetic diseases

About Prenatal DNA Sequencing Prenatal DNA sequencing is the method of DNA sequencing where DNA isolated from the blood of pregnant women to reveal the full genetic code of a fetus. It is useful in detecting disorders such as Down syndrome, cystic fibrosis, thalassemia, and cancer. Technavio’s analysts forecast...

  • Genetic Disorder
  • Agilent Technologies, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Illumina, Inc.
  • Natera, Inc.

2018 Japan Nucleic Acid Testing/ NAT Market: Supplier Shares and Strategies, Country Volume and Sales Segment Forecasts--Infectious and Genetic Diseases, Cancer, Forensic and Paternity Testing Highlights Comprehensive ##, ##-page market segmentation analysis of the Japanese NAT

  • Genetic Disorder
  • Pathology
  • Japan
  • Demand
  • Forecast

Nucleic Acid Testing/ NAT Market: Supplier Shares and Strategies, Country Volume and Sales Segment Forecasts--Infectious and Genetic Diseases, Cancer, Forensic and Paternity Testing Highlights Comprehensive ##, ##-page market segmentation analysis of the US NAT market.

  • Genetic Disorder
  • Pathology
  • United States
  • Demand
  • Forecast

Nucleic Acid Testing/ NAT Market: Supplier Shares and Strategies, Country Volume and Sales Segment Forecasts--Infectious and Genetic Diseases, Cancer, Forensic and Paternity Testing Highlights Comprehensive ##, ##-page market segmentation analysis of the UK NAT market.

  • Genetic Disorder
  • Pathology
  • United Kingdom
  • Demand
  • Forecast

2018 Germany Nucleic Acid Testing/ NAT Market: Supplier Shares and Strategies, Country Volume and Sales Segment Forecasts--Infectious and Genetic Diseases, Cancer, Forensic and Paternity Testing Highlights Comprehensive ##, ##-page market segmentation analysis of the German NA

  • Genetic Disorder
  • Pathology
  • Germany
  • Demand
  • Forecast

2018 Italy Nucleic Acid Testing/ NAT Market: Supplier Shares and Strategies, Country Volume and Sales Segment Forecasts--Infectious and Genetic Diseases, Cancer, Forensic and Paternity Testing Highlights Comprehensive ##, ##-page market segmentation analysis of the Italian NAT

  • Genetic Disorder
  • Pathology
  • Italy
  • Demand
  • Forecast

2018 Spain Nucleic Acid Testing/ NAT Market: Supplier Shares and Strategies, Country Volume and Sales Segment Forecasts--Infectious and Genetic Diseases, Cancer, Forensic and Paternity Testing Highlights Comprehensive ##, ##-page market segmentation analysis of the Spanish NAT

  • Genetic Disorder
  • Pathology
  • Spain
  • Demand
  • Forecast

Ten-year test volume and reagent sales forecasts for the following categories: & nbsp; & nbsp; & nbsp; - & nbsp; Infectious Diseases Genetic Diseases & nbsp; & nbsp; & nbsp; - & nbsp; Cancer & nbsp; & nbsp; & nbsp; - & nbsp; Paternity Testing/

  • Genetic Disorder
  • Molecular Diagnostic
  • Spain
  • Demand
  • Forecast
  • JAPAN - CYSTIC FIBROSIS THERAPEUTICS MARKET (MILLION US$), 2014 - 2016
  • 6.2 CANADA CYSTIC FIBROSIS THERAPEUTICS MARKET & FORECAST

The market for Cystic Fibrosis Therapeutics is anticipated to grow with double digit CAGR during the forecasting period. Cystic fibrosis is among the most common life-threatening genetic disorders worldwide. It is caused by defects in a single gene known as the cystic fibrosis transmembrane conductance regulator, or CFTR. The increasing...

  • Genetic Disorder
  • World
  • Market Size
  • AbbVie Inc.
  • Editas Medicine, Inc.
  • GLOBAL CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2015 & 2022
  • 1.1 DEFINITION

Cystic fibrosis is a genetic disease.

  • Genetic Disorder
  • AbbVie Inc.
  • Allergan plc
  • Pharmaxis Ltd
  • Vertex Pharmaceuticals Incorporated
  • MARKET DEFINIION
  • 5.1 CURRENT MARKET SCENARIO

The Europe genetic testing market is expected to register a CAGR of 12.3% during the forecast period of 2018–2023. Genetic testing has become quite prevalent in Europe over the last few years, with recent developments in molecular medicine expected to provide further impetus to this critical area. The integration of these technologies into...

  • Genetic Disorder
  • Europe
  • World
  • Illumina, Inc.
  • Roche Group
  • Carrier Screening Market: Revenue in USD million, by Disease Type, Global, 2018-2023
  • 4. KEY INFERENCES

The global carrier screening market is expected to account for a value of USD 2,237 million, registering a CAGR of about 9.8% during the forecast period (2018-2023). Carrier screening is one of the genetic tests that provide the data on whether a particular person carries a gene for certain genetic disorders or not. When the test is performed...

  • Genetic Disorder
  • 23andMe, Inc.
  • Cepheid
  • Illumina, Inc.
  • Sequenom, Inc.
  • 1.1 DEFINITION
  • 5 Cystic Fibrosis Market, By Treatment Method

Cystic fibrosis is a genetic disease.

  • Genetic Disorder
  • AbbVie Inc.
  • Allergan plc
  • Pharmaxis Ltd
  • Vertex Pharmaceuticals Incorporated

GENETIC FACTORS ARE ALSO A CONTRIBUTOR TO IPF; AROUND ## IN ## PEOPLE WITH IPF HAVE ANOTHER FAMILY MEMBER WITH THE DISEASE DUE TO A DISEASE CALLED FAMILIAL IDIOPATHIC FIBROSIS.

  • Genetic Disorder
  • World
  • Market Size
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Proportion of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) to Genetic Disorders
  • Proportion of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) to Genetic Disorders

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Global Clinical Trials Review, H2, 2015 Summary GlobalData's clinical trial report, “Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Global Clinical Trials Review, H2, 2015" provides an overview of Adrenoleukodystrophy (Adrenomyeloneuropathy/...

  • Genetic Disorder
  • World
  • Aldagen, Inc.
  • Asklepion Pharmaceuticals, LLC
  • Nutra Pharma Corporation
  • Clinical Trials by E7 Countries: Proportion of Primary Immune Deficiency (PID) to Genetic Disorders Clinical Trials
  • Clinical Trials by G7 Countries: Proportion of Primary Immune Deficiency (PID) to Genetic Disorders Clinical Trials

Primary Immune Deficiency (PID) Global Clinical Trials Review, H2, 2015 Summary GlobalData's clinical trial report, “Primary Immune Deficiency (PID) Global Clinical Trials Review, H2, 2015" provides an overview of Primary Immune Deficiency (PID) clinical trials scenario. This report provides top line data relating to the...

  • Genetic Disorder
  • World
  • Baxter International Inc.
  • Biotest AG
  • CSL Limited
  • II. Etiology and Genetics of Cystic Fibrosis
  • 1. CYSTIC FIBROSIS: DISEASE OVERVIEW

Cystic fibrosis is a rare genetic disorder caused by the mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene located on chromosome 7. It largely affects the lungs and digestive system, and causes the secretions to become thick and sticky. The individuals with cystic fibrosis develop lung disease, resulting...

  • Cystic Fibrosis
  • Genetic Disorder
  • World
  • AbbVie Inc.
  • Vertex Pharmaceuticals Incorporated
  • PULMONARY HYPERTENSION

Engages in the development of drugs in areas such as immuno-oncology, oncology, immunoscience, virology, cardiovascular, fibrotic diseases, and metabolic and genetically defined diseases.

  • Genetic Disorder
  • AstraZeneca PLC
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Novartis AG

(USA) ##.

  • Genetic Disorder
  • Pharmaceutical
  • China
  • World
  • Market Shares
  • INTRODUCTION

IT IS AN AUTOSOMAL RECESSIVE GENETIC disorder caused by mutations in the CF gene.

  • Genetic Disorder
  • North America
  • United States
  • AstraZeneca PLC
  • Novartis AG

Cystic fibrosis and bone disease: are we missing a genetic link?

  • Genetic Disorder
  • Canada
  • France
  • Italy
  • Forecast
  • Snapshot of Cystic Fibrosis
  • 06. Introduction

About Cystic Fibrosis Cystic fibrosis, also known as mucoviscidosis, is a genetically inherited disease. The primary symptoms of cystic fibrosis include high salt content in the sweat, breathing difficulties, secretion of abnormally viscous mucus, respiratory complications, difficulties related to digestion, and growth anomalies. Cystic...

  • Genetic Disorder
  • Europe
  • Actavis plc
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.

Cystic fibrosis and bone disease: are we missing a genetic link?

  • Genetic Disorder
  • Forest Laboratories, Inc.
  • Novartis AG
  • Pharmaxis Ltd
  • Vertex Pharmaceuticals Incorporated
  • 7.3 GENETIC DISORDERS
  • VIRAL VECTOR MANUFACTURING MARKET FOR GENETIC DISORDERS, BY REGION, 2016-2023 (USD MILLION)

The global viral vector manufacturing market is projected to grow at a CAGR of 20.0%. The viral vector manufacturing market is expected to reach USD 815.8 million by 2023 from an estimated USD 327.8 million in 2018, at a CAGR of 20.0%. The growth of this market is expected to be driven by rising prevalence of target diseases and disorders,...

  • Genetic Disorder
  • Viral Vector
  • North America
  • United States
  • Market Size
  • PROPORTION OF SPINOCEREBELLAR ATAXIA (SCA) TO GENETIC DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2018*
  • PROPORTION OF SPINOCEREBELLAR ATAXIA (SCA) TO GENETIC DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2018*

Spinocerebellar Ataxia (SCA) Global Clinical Trials Review, H2, 2018 Summary GlobalData’s clinical trial report, “Spinocerebellar Ataxia (SCA) Global Clinical Trials Review, H2, 2018" provides an overview of Spinocerebellar Ataxia (SCA) clinical trials scenario.This report provides top line data...

  • Clinical Trial
  • Genetic Disorder
  • World
  • Product Initiative
  • Kissei Pharmaceutical Co., Ltd.
  • Proportion of Severe Combined Immune Deficiency (SCID) to Genetic Disorders Clinical Trials, G7 Countries (%),
  • CLINICAL TRIALS BY E7 COUNTRIES: PROPORTION OF SEVERE COMBINED IMMUNE DEFICIENCY (SCID) TO GENETIC DISORDERS CLINICAL TRIALS

Severe Combined Immune Deficiency (SCID) Global Clinical Trials Review, H2, 2018 Summary GlobalData’s clinical trial report, “Severe Combined Immune Deficiency (SCID) Global Clinical Trials Review, H2, 2018" provides an overview of Severe Combined Immune Deficiency (SCID) clinical trials scenario.This...

  • Genetic Disorder
  • Therapy
  • World
  • Product Initiative
  • GlaxoSmithKline plc
  • CLINICAL TRIALS BY G7 COUNTRIES: PROPORTION OF PRADER-WILLI SYNDROME (PWS) TO GENETIC DISORDERS CLINICAL TRIALS
  • PROPORTION OF PRADER-WILLI SYNDROME (PWS) TO GENETIC DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2018*

Prader-Willi Syndrome (PWS) Global Clinical Trials Review, H1, 2018 Summary GlobalData’s clinical trial report, “Prader-Willi Syndrome (PWS) Global Clinical Trials Review, H1, 2018" provides an overview of Prader-Willi Syndrome (PWS) clinical trials scenario.This report provides top line data relating...

  • Genetic Disorder
  • Pharmaceutical
  • Therapy
  • World
  • Product Initiative
  • Proportion of Osteogenesis Imperfecta to Genetic Disorders Clinical Trials, G7 Countries (%), 2015*
  • Proportion of Osteogenesis Imperfecta to Genetic Disorders Clinical Trials, E7 Countries (%), 2015*

Osteogenesis Imperfecta Global Clinical Trials Review, H1, 2018 Summary GlobalData’s clinical trial report, “Osteogenesis Imperfecta Global Clinical Trials Review, H1, 2018" provides an overview of Osteogenesis Imperfecta clinical trials scenario.This report provides top line data relating to the...

  • Genetic Disorder
  • Therapy
  • World
  • Product Initiative
  • Mereo Biopharma Group Limited